.png)
Today we're talking life sciences investment trends and risks with David Sans, an investment banker with an academic background in chemical engineering and molecular modeling, and a professional background that began in Big Pharma and shifted to investing over 15 years ago. This Business of Biotech podcast conversation covers patent cliff implications, hot therapeutic areas and delivery mechanisms, geopolitical risks, alternative funding strategies, and private equity's move upstream to pre-clinical and pre-revenue biotech.
Subscribe to the podcast on your preferred platform and watch the videocast at lifescienceleader.com.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
---
#businessofbiotech #biopharma #biotech
Subscribe to the podcast:
Apple - https://podcasts.apple.com/us/podcast/business-of-biotech/id1508008606?uo=4
Spotify - https://open.spotify.com/show/5NhjpDeHzVlXPVqT9ezKwA
YouTube - https://www.youtube.com/playlist?list=PLFXsCNKV78rWNPmqIA8b2dKYLPYYv28wb
Did you miss our previous article...
https://trendinginbusiness.business/trending-videos/-univest-app-walkthrough
